Based on the provided data, the antiarrhythmic medicine sales in Spain are forecasted as follows: 22.8 million Euros in 2024, 22.9 million Euros in 2025, 23.0 million Euros in 2026, 23.1 million Euros in 2027, and 23.1 million Euros in 2028. In 2023, the value stood at 22.7 million Euros. Considering the year-on-year variations, the sales are expected to grow steadily, with minimal increases each year.
Year-on-year percentage variations over the last two years show a 0.44% increase from 2023 to 2024 and a similar growth trend from 2024 to 2025. The Compound Annual Growth Rate (CAGR) over the last five years indicates a modest average annual growth rate of around 0.35%.
Future trends to watch for include potential advancements in antiarrhythmic drug formulations, healthcare policy changes affecting drug availability, and demographic shifts influencing the prevalence of arrhythmias in Spain, which could impact overall sales expectations.
